The estimated Net Worth of Vitalife Partners (Israel) ... is at least $702 millier dollars as of 26 June 2017. Vitalife Israel owns over 21,782 units of Rewalk Robotics Ltd stock worth over $356,895 and over the last 8 years Vitalife sold RWLK stock worth over $345,546.
Vitalife has made over 10 trades of the Rewalk Robotics Ltd stock since 2016, according to the Form 4 filled with the SEC. Most recently Vitalife sold 21,782 units of RWLK stock worth $66,435 on 26 June 2017.
The largest trade Vitalife's ever made was selling 21,782 units of Rewalk Robotics Ltd stock on 26 June 2017 worth over $66,435. On average, Vitalife trades about 5,457 units every 40 days since 2016. As of 26 June 2017 Vitalife still owns at least 339,900 units of Rewalk Robotics Ltd stock.
You can see the complete history of Vitalife Israel stock trades at the bottom of the page.
Over the last 9 years, insiders at Rewalk Robotics Ltd have traded over $7,660,045 worth of Rewalk Robotics Ltd stock and bought 8,170,475 units worth $6,701,652 . The most active insiders traders include Global Fund Ii Lp Lind Glob..., Glenn P Muir et Wayne Weisman. On average, Rewalk Robotics Ltd executives and independent directors trade stock every 26 days with the average trade being worth of $88,081. The most recent stock trade was executed by Global Fund Ii Lp Lind on 17 November 2023, trading 54,917 units of RWLK stock currently worth $40,089.
exoskeleton leader rewalk robotics, inc. (formerly argo medical technologies) develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury (sci). rewalk’s mission is to fundamentally change the health and life experiences of individuals with spinal cord injury. founded in 2001, rewalk has headquarters in the us, israel and germany. rewalk robotics' rewalk is a wearable robotic exoskeleton that provides powered hip and knee motion to enable individuals with spinal cord injury (sci) to stand upright and walk. rewalk is the only exoskeleton with fda clearance via clinical studies and extensive performance testing for personal use rewalk has been tested extensively in the u.s., europe, and israel. the rewalk system is supported by the most published data of all exoskeleton systems in the rehabilitation market, and is used by more people worldwide than all other exoskeleton systems combined. the company offers two products: rewalk personal and the
Rewalk Robotics Ltd executives and other stock owners filed with the SEC include: